Suppr超能文献

小泛素样修饰与乳腺癌的发生发展相关

SUMOylation Wrestles With the Occurrence and Development of Breast Cancer.

作者信息

Qin Yuanyuan, Yuan Hong, Chen Xu, Yang Xinyi, Xing Zhengcao, Shen Yajie, Dong Wanying, An Siming, Qi Yitao, Wu Hongmei

机构信息

Key Laboratory of the Ministry of Education for Medicinal Resources and Natural Pharmaceutical Chemistry, National Engineering Laboratory for Resource Developing of Endangered Chinese Crude Drugs in Northwest of China, College of Life Sciences, Shaanxi Normal University, Xi'an, China.

出版信息

Front Oncol. 2021 Apr 21;11:659661. doi: 10.3389/fonc.2021.659661. eCollection 2021.

Abstract

Breast cancer has the highest incidence among cancers and is the most frequent cause of death in women worldwide. The detailed mechanism of the pathogenesis of breast cancer has not been fully elucidated, and there remains a lack of effective treatment methods for the disease. SUMOylation covalently conjugates a large amount of cellular proteins, and affects their cellular localization and biological activity to participate in numerous cellular processes. SUMOylation is an important process and imbalance of SUMOylation results in the progression of human diseases. Increasing evidence shows that numerous SUMOylated proteins are involved in the occurrence and development of breast cancer. This review summarizes a series of studies on protein SUMOylation in breast cancer in recent years. The study of SUMOylated proteins provides a comprehensive understanding of the pathophysiology of breast cancer and provides evolving therapeutic strategies for the treatment of breast cancer.

摘要

乳腺癌在各类癌症中发病率最高,是全球女性最常见的死因。乳腺癌发病的详细机制尚未完全阐明,且该疾病仍缺乏有效的治疗方法。小泛素样修饰(SUMOylation)可共价结合大量细胞蛋白,并影响其细胞定位和生物活性,从而参与众多细胞过程。SUMOylation是一个重要过程,SUMOylation失衡会导致人类疾病的进展。越来越多的证据表明,众多SUMO化修饰的蛋白质参与了乳腺癌的发生和发展。本文综述了近年来关于乳腺癌中蛋白质SUMOylation的一系列研究。对SUMO化修饰蛋白质的研究有助于全面了解乳腺癌的病理生理学,并为乳腺癌治疗提供不断发展的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ff/8097099/5f19d3a5930e/fonc-11-659661-g001.jpg

相似文献

1
SUMOylation Wrestles With the Occurrence and Development of Breast Cancer.
Front Oncol. 2021 Apr 21;11:659661. doi: 10.3389/fonc.2021.659661. eCollection 2021.
4
The important roles of protein SUMOylation in the occurrence and development of leukemia and clinical implications.
J Cell Physiol. 2021 May;236(5):3466-3480. doi: 10.1002/jcp.30143. Epub 2020 Nov 5.
6
RAS GTPases are modified by SUMOylation.
Oncotarget. 2017 Dec 15;9(4):4440-4450. doi: 10.18632/oncotarget.23269. eCollection 2018 Jan 12.
8
Negative regulation of C/EBPbeta1 by sumoylation in breast cancer cells.
PLoS One. 2011;6(9):e25205. doi: 10.1371/journal.pone.0025205. Epub 2011 Sep 28.
9
The Ubiquitin-Like SUMO System and Heart Function: From Development to Disease.
Circ Res. 2016 Jan 8;118(1):132-44. doi: 10.1161/CIRCRESAHA.115.307730.
10

引用本文的文献

2
MicroRNA-145-5p inhibits the tumorigenesis of breast cancer through SENP2-regulated ubiquitination of ERK2.
Cell Mol Life Sci. 2024 Nov 23;81(1):461. doi: 10.1007/s00018-024-05505-8.
3
The role of NOP58 in prostate cancer progression through SUMOylation regulation and drug response.
Front Pharmacol. 2024 Oct 18;15:1476025. doi: 10.3389/fphar.2024.1476025. eCollection 2024.
4
Crosstalk between SUMOylation and other post-translational modifications in breast cancer.
Cell Mol Biol Lett. 2024 Aug 10;29(1):107. doi: 10.1186/s11658-024-00624-3.
5
Editorial: Role of the SUMOylation in cancer regulation.
Front Mol Biosci. 2023 Aug 31;10:1236230. doi: 10.3389/fmolb.2023.1236230. eCollection 2023.
7
The Role of SUMO E3 Ligases in Signaling Pathway of Cancer Cells.
Int J Mol Sci. 2022 Mar 26;23(7):3639. doi: 10.3390/ijms23073639.

本文引用的文献

1
The important roles of protein SUMOylation in the occurrence and development of leukemia and clinical implications.
J Cell Physiol. 2021 May;236(5):3466-3480. doi: 10.1002/jcp.30143. Epub 2020 Nov 5.
2
Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1.
Br J Cancer. 2020 Nov;123(11):1665-1672. doi: 10.1038/s41416-020-01065-3. Epub 2020 Sep 17.
3
The SUMO-specific protease SENP1 deSUMOylates p53 and regulates its activity.
J Cell Biochem. 2021 Feb;122(2):189-197. doi: 10.1002/jcb.29838. Epub 2020 Aug 12.
4
PIAS1 and TIF1γ collaborate to promote SnoN SUMOylation and suppression of epithelial-mesenchymal transition.
Cell Death Differ. 2021 Jan;28(1):267-282. doi: 10.1038/s41418-020-0599-8. Epub 2020 Aug 7.
5
SUMO: From Bench to Bedside.
Physiol Rev. 2020 Oct 1;100(4):1599-1619. doi: 10.1152/physrev.00025.2019.
6
Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies.
Int J Environ Res Public Health. 2020 Mar 20;17(6):2078. doi: 10.3390/ijerph17062078.
7
A SUMOylation-dependent HIF-1α/CLDN6 negative feedback mitigates hypoxia-induced breast cancer metastasis.
J Exp Clin Cancer Res. 2020 Feb 24;39(1):42. doi: 10.1186/s13046-020-01547-5.
8
Writing and erasing MYC ubiquitination and SUMOylation.
Genes Dis. 2019 Jul 24;6(4):359-371. doi: 10.1016/j.gendis.2019.05.006. eCollection 2019 Dec.
9
Targeting PML in triple negative breast cancer elicits growth suppression and senescence.
Cell Death Differ. 2020 Apr;27(4):1186-1199. doi: 10.1038/s41418-019-0407-5. Epub 2019 Oct 1.
10
PES1 is a critical component of telomerase assembly and regulates cellular senescence.
Sci Adv. 2019 May 15;5(5):eaav1090. doi: 10.1126/sciadv.aav1090. eCollection 2019 May.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验